Carbogen Inhalation Therapy — CPB 0428 | AETNA Coverage Update

Aetna modified CPB 0428, its carbogen inhalation therapy coverage policy, effective September 26, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0428 governing carbogen inhalation therapy. This policy covers a broad set of oncology, neurology, and ophthalmology diagnoses — over 110 ICD-10-CM codes spanning head and neck malignancies, cervical cancer, prostate cancer, bladder cancer, epilepsy, retinal vascular occlusions, optic nerve disorders, and sudden hearing loss. If your practice bills carbogen therapy for any of these diagnoses under Aetna, this coverage policy update affects your claims.

Quick-Reference Table

Aetna Carbogen Inhalation Therapy Coverage Criteria and Medical Necessity Requirements 2025

Carbogen — a mixture of carbon dioxide and oxygen — has been studied as a radiosensitizing agent and as a vasodilator for conditions involving vascular compromise. Aetna's coverage policy under CPB 0428 ties coverage directly to specific diagnoses. If the ICD-10-CM code on your claim doesn't appear in the policy's accepted list, expect a claim denial.

The real issue here is medical necessity documentation. Aetna's clinical policy bulletins consistently require that carbogen inhalation therapy be medically necessary for the specific covered indication — not just clinically relevant. That means your documentation needs to support the diagnosis code you're billing, not just reference carbogen as an adjunct to radiation or as a vascular treatment.

The Aetna carbogen inhalation therapy coverage policy applies across a wide range of tumor sites. Head and neck cancers — including malignant neoplasms of the lip (C00.0–C00.9), oral cavity (C01–C06.9), major salivary glands (C07–C08.9), nasopharynx (C11.0–C11.9), nasal cavities and accessory sinuses (C30.0–C31.9), and larynx (C32.0–C32.9) — are all represented in the diagnosis code list. Melanoma of the head and neck (C43.0–C43.4) and melanoma in situ (D03.0–D03.4) are also listed.

Beyond head and neck oncology, CPB 0428 Aetna covers carbogen therapy for cervical cancer (C53.0–C53.9), prostate cancer (C61), and bladder cancer (C67.0–C67.9). The policy also extends to malignant neoplasm of the head, face, and neck (C76.0). That's a broad oncology footprint — and it matters for radiation oncology practices that use carbogen as a radiosensitizer alongside external beam radiation.

Outside oncology, the policy lists epilepsy and recurrent seizures (G40.001–G40.919), retinal vascular occlusions (H34.0–H34.9), disorders of the optic nerve and visual pathways (H46.00–H47.9), and sudden idiopathic hearing loss (H91.20–H91.22). These are distinct clinical applications. If you bill carbogen for sudden hearing loss or retinal occlusion, confirm that your documentation explicitly supports that specific diagnosis — not just the symptom.

Prior authorization requirements for carbogen inhalation therapy under Aetna vary by plan. Check the member's specific benefit plan before scheduling treatment. If you're not sure whether prior auth applies to a particular account, call Aetna provider services before the effective date of September 26, 2025.

Aetna Carbogen Inhalation Therapy Exclusions and Non-Covered Indications

The policy data from CPB 0428 does not provide a separate explicit exclusions list within the data provided here. However, the structure of Aetna clinical policy bulletins is consistent: any indication not listed among the covered ICD-10-CM codes is considered experimental, investigational, or not medically necessary.

That's the practical exclusion rule for carbogen inhalation therapy billing under Aetna. If your diagnosis code isn't in the table below, assume it's not covered. Don't assume silence equals coverage — it doesn't.

If you're treating a patient with a diagnosis that seems clinically similar to a covered indication but maps to a different ICD-10-CM code, talk to your compliance officer before submitting the claim.

Coverage Indications at a Glance

Aetna Carbogen Inhalation Therapy Billing Guidelines and Action Items 2025

Carbogen inhalation therapy billing is niche, but the claims exposure is real. Here's what to do before and after the September 26, 2025 effective date.

CPT, HCPCS, and ICD-10 Codes for Carbogen Inhalation Therapy Under CPB 0428

The policy data for CPB 0428 does not include specific CPT or HCPCS procedure codes. Aetna's carbogen inhalation therapy coverage policy is structured around ICD-10-CM diagnosis codes — the indication drives coverage, not a specific procedure code. If your billing system requires a procedure code crosswalk, work with your billing consultant to confirm the correct code for carbogen delivery in your setting.

Key ICD-10-CM Diagnosis Codes — CPB 0428 Covered Indications

The policy data notes 30 additional ICD-10-CM codes beyond those listed above. Access the full list at app.payerpolicy.org/p/aetna/0428.